Skip to Content

Genitourinary Cancer Trials

MOSAIC-P: Mindfulness Online for Symptom Alleviation and Improvement in Cancer of the Prostate 
Aims:The purpose of the study is to test a four-week mindfulness program that is intended to reduce stress and improve the quality of life in men with prostate cancer that has spread to other parts of the body.   Each participant will be separated into one of two meeting locations at random, although the class content will be the same. Classes will be held: 1) in-person at a NorthShore facility;  or 2) online allowing men to participate while staying at home. 
Principal Investigator: Britt Hanson, DO
IRB Approval Number: EH15-403
Sponsor: NorthShore University HealthSystem 
Contact: Interested patients should contact study coordinator Nick Kirwen at 847.503.4281
Open to Enrollment: Yes

SPORE: Tissue, Blood, and Urine Banking for the Robert H. Lurie Comprehensive Cancer Center Prostate Tissue Bank
Aims: This study involves the banking (storing) of prostate tissue, blood and urine. Information from the patient's medical records and treatment will be followed for an indefinite amount of time up to 75 years or more. The purpose of the study is to enable cancer researchers and other investigators attain a better understanding of the development of prostate cancer, its treatment, prevention, and cure.
Diagnosis: Prostate
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH01-129
Sponsor: Robert H. Lurie Comprehensive Cancer Center
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

Astellas ONC-MA-1004: A Prospective Observational Cohort Study of Patients with Castration-Resistant Prostate Cancer (CRPC) in the United States (TRUMPET)
Aims: The purpose of this study to to describe patterns of care, disease assessment methods, treatment decisions, treatment settings, physician referral patterns and to find out how your CRPC symptoms have improved while on therapy.
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH15-219
Sponsor: Astellas Scientific and Medical Affairs
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

PCCTC c16-168: A Randomized Phase II  Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (CRPC) with DNA Repair Defects
Aims: The main purpose is to study abiraterone alone, olaparib alone or the combination of the two drugs to see which works better.
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH17/285
Sponsor: University of Chicago/PCCTC
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

AFT-19: A Phase 3 Study of Androgen Annihiliation in High-Risk Biochemically Relapsed Prostate Cancer
Aims: The purpose of this study which of the 3 treatment regimens is better at treating prostate Cancer:  1) degarelix, 2) degarelix and apalutamide, or 3) degarelix and apalutamide and abiraterone acetate/prednisone
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH17-287
Sponsor: Alliance Foundation Trial
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

Janssen 64091742PCR2001 A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration Resistant Prostate Cancer and DNA-Repair Anomalies.
Aims: The main purpose of this study is to see if niraparib is useful to treat men with advanced prostate cancer. The safety of niraparib will also be studied.
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH16-364
Sponsor: Janssen Research and Development, LLC
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

UC13-0979: A Phase I/II Trial of Enzalutamide Plus Glucocorticoid Receptor Antagonist Mifepristone for Patient with Metastatic Castration Resistant Prostate Cancer (CRPC)
Aims: The purpose of this study is to see if mifepristone can be safely and effectively added to enzalutamide to treat prostate cancer.
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH17-189
Sponsor: University of Chicago
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes